Incident low muscle mass is associated with greater lung disease and lower circulating leptin in a tobacco-exposed longitudinal cohort.

Zou RH, Nouraie SM, Karoleski C, Zhang Y, Sciurba FC, Forman DE, Bon J. Incident low muscle mass is associated with greater lung disease and lower circulating leptin in a tobacco-exposed longitudinal cohort. Respiratory Research. 2023 Sep 22; 24(1):224.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: Muscle loss is prevalent in chronic obstructive pulmonary disease (COPD). Prior studies evaluating musculoskeletal dysfunction in COPD have focused on individuals with baseline low muscle mass. Currently, there is limited data evaluating clinical characteristics and outcomes associated with progression to incident low muscle mass in a tobacco-exposed cohort of individuals with baseline normal muscle mass. METHODS: We evaluated 246 participants from a single-center longitudinal tobacco-exposed cohort with serial spirometry, thoracic imaging, dual energy x-ray absorptiometry (DXA) measurements, walk testing, and plasma adipokine measurements. DXA-derived fat free mass index (FFMI) and appendicular skeletal mass index (ASMI) were used as surrogates for muscle mass. Participants with incident low muscle mass (LM) at follow-up were characterized by FFMI? < 18.4 kg/m in males and < 15.4 kg/m in females and/or ASMI? < 7.25 kg/m in males and < 5.67 kg/m in females. RESULTS: Twenty-five (10%) participants progressed to incident low muscle mass at follow-up. At baseline, the LM subgroup had greater active smoking prevalence (60% v. 38%, p? = 0.04), lower FFMI (17.8 ± 1.7 kg/m v. 19.7 ± 2.9 kg/m, p? = 0.002), lower ASMI (7.3 ± 0.9 kg/m v. 8.2 ± 1.2 kg/m, p? = 0.0003), and lower plasma leptin (14.9 ± 10.1 ng/mL v. 24.0 ± 20.9 ng/mL, p? = 0.04). At follow-up, the LM subgroup had higher COPD prevalence (68% v. 43%, p? = 0.02), lower FEV/FVC (0.63 ± 0.12 v. 0.69 ± 0.12, p? = 0.02), lower %DLco (66.5 ± 15.9% v. 73.9 ± 16.8%, p? = 0.03), and higher annual rate of FFMI decline (-0.17 kg/m/year v. -0.04 kg/m/year, p? = 0.006). There were no differences in age, gender distribution, pack years smoking history, or walk distance. CONCLUSIONS: We identified a subgroup of tobacco-exposed individuals with normal baseline muscle mass who progressed to incident DXA-derived low muscle mass. This subgroup demonstrated synchronous lung disease and persistently low circulating leptin levels. Our study suggests the importance of assessing for muscle loss in conjunction with lung function decline when evaluating individuals with tobacco exposure.